Astrazeneca (AZN) Other Accumulated Expenses (2009 - 2026)

Astrazeneca (AZN) has reported Other Accumulated Expenses for 18 consecutive years, with -$2.2 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 5.74% year-over-year to -$2.2 billion; the TTM figure through Mar 2026 stood at -$2.2 billion (down 5.74% YoY), while the FY2025 annual figure was -$2.4 billion, down 34.41% from the prior year.
• Other Accumulated Expenses came in at -$2.2 billion for Q1 2026 at Astrazeneca, up from -$2.4 billion in the prior quarter.
• The five-year high for Other Accumulated Expenses was -$1.6 billion in Q2 2025, with the low at -$4.9 billion in Q3 2022.
• Average Other Accumulated Expenses over 5 years is -$2.7 billion, with a median of -$2.4 billion recorded in 2025.
• Across the five-year window, Other Accumulated Expenses soared 54.04% in 2023 and plunged 34.41% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at -$4.3 billion in 2022, then surged by 37.7% to -$2.7 billion in 2023, then jumped by 33.46% to -$1.8 billion in 2024, then slumped by 34.41% to -$2.4 billion in 2025, then advanced by 9.42% to -$2.2 billion in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered -$2.2 billion, -$2.4 billion, and -$2.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.